AUA 2017: Long-term combination treatment with solifenacin and mirabegron is effective and well-tolerated in patients with overactive bladder
Primary objective was for safety, frequency of adverse events. Secondary objectives involved efficacy as in the change from baseline to end of treatment in the mean number of UI episodes/24 hr and micturition/ 24 hr. Mean voided volume per micturition, OAB-q Symptom Bother Score and TS-VAS were additional variables. 1,819 patients were enrolled and were randomized in a 12-week double-blind treatment course to 3 arms: 1) combination Soli + Mira or 2) Soli alone, or 3) Mira alone. All treatments were generally well-tolerated. Slight increase frequency of overall AEs in the combination group (Combination + Soli alone=dry mouth; Mira=Nasopharyngitis). Efficacy indicated that clear and clinically relevant improvements with combination compared with each monotherapy. Also, combination treatment did not reveal any new safety concerns.
Presented by: Christian Gratzke, MD, University of Munich
Written by: Diane K. Newman, DNP, FAAN, BCB-PMD, Perelman School of Medicine, University of Pennsylvania
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA